UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The leukemic stem cell niche: current concepts and therapeutic opportunities

Blood, 2009-08, Vol.114 (6), p.1150-1157

2009

Volltextzugriff (PDF)

Direct inhibition of the NOTCH transcription factor complex

Nature (London), 2009-11, Vol.462 (7270), p.182-188

2009

Volltextzugriff (PDF)

FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system

Cell stem cell, 2007-08, Vol.1 (2), p.140-152

2007

Volltextzugriff (PDF)

Unifying mechanism for different fibrotic diseases

Proceedings of the National Academy of Sciences - PNAS, 2017-05, Vol.114 (18), p.4757-4762

2017

Volltextzugriff (PDF)

Myeloproliferative disorders

Blood, 2008-09, Vol.112 (6), p.2190-2198

2008

Volltextzugriff (PDF)

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

Blood, 2014-05, Vol.123 (22), p.e123-e133

2014

Volltextzugriff (PDF)

Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells

Cell stem cell, 2015-08, Vol.17 (2), p.165-177

2015

Volltextzugriff (PDF)

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

Nature reviews. Cancer, 2007-09, Vol.7 (9), p.673-683

2007

Volltextzugriff (PDF)

The roles of FLT3 in hematopoiesis and leukemia

Blood, 2002-09, Vol.100 (5), p.1532-1542

2002

Volltextzugriff (PDF)

The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade

Immunity (Cambridge, Mass.), 2022-04, Vol.55 (4), p.671-685.e10

2022

Volltextzugriff (PDF)

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Journal of clinical oncology, 2010-10, Vol.28 (28), p.4339-4345

2010

Volltextzugriff (PDF)

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

Journal of clinical oncology, 2011-03, Vol.29 (7), p.789-796

2011

Volltextzugriff (PDF)

Drug development and clinical trials--the path to an approved cancer drug

Nature reviews. Clinical oncology, 2012-04, Vol.9 (4), p.215-222

2012

Volltextzugriff (PDF)

FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress

Cell, 2007-01, Vol.128 (2), p.325-339

2007

Volltextzugriff (PDF)

Differential niche and Wnt requirements during acute myeloid leukemia progression

Blood, 2011-09, Vol.118 (10), p.2849-2856

2011

Volltextzugriff (PDF)

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Blood, 2009-07, Vol.114 (1), p.144-147

2009

Volltextzugriff (PDF)

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

Blood, 2010-02, Vol.115 (7), p.1406-1415

2010

Volltextzugriff (PDF)

Oncogenes in Myeloproliferative Disorders

Cell cycle (Georgetown, Tex.), 2007-03, Vol.6 (5), p.550-566

2007

Volltextzugriff (PDF)

Drug therapy for acute myeloid leukemia

Blood, 2005-08, Vol.106 (4), p.1154-1163

2005

Volltextzugriff (PDF)

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth

Science signaling, 2009-11, Vol.2 (97), p.ra73

2009

Volltextzugriff (PDF)

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias

Cell, 2011-09, Vol.146 (5), p.697-708

2011

Volltextzugriff (PDF)

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

Molecular cancer therapeutics, 2013-08, Vol.12 (8), p.1442-1452

2013

Volltextzugriff (PDF)

Activating mutations in ALK provide a therapeutic target in neuroblastoma

Nature (London), 2008-10, Vol.455 (7215), p.975-978

2008

Volltextzugriff (PDF)

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Cell, 2009-05, Vol.137 (5), p.821-834

2009

Volltextzugriff (PDF)

1 – 25 von 451

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(427)
Mit Volltextzugriff
(422)

Publikationsform

Sprache

Englisch
(449)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(264)
Life Sciences & Biomedicine
(240)
Humans
(211)
Biological And Medical Sciences
(137)
Animals
(130)
Medical Sciences
(122)
Mice
(112)
Hematology
(104)
Hematologic And Hematopoietic Diseases
(101)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(89)
Cell Biology
(67)
Mutation
(67)
Female
(62)
Oncology
(57)
Biochemistry & Molecular Biology
(50)
Male
(47)
Myeloproliferative Disorders - Genetics
(37)
Leukemia
(34)
Adult
(32)
Middle Aged
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The leukemic stem cell niche: current concepts and therapeutic opportunities

Direct inhibition of the NOTCH transcription factor complex

FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system

Unifying mechanism for different fibrotic diseases

Myeloproliferative disorders

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis

Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

The roles of FLT3 in hematopoiesis and leukemia

The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

Drug development and clinical trials--the path to an approved cancer drug

FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress

Differential niche and Wnt requirements during acute myeloid leukemia progression

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

Oncogenes in Myeloproliferative Disorders

Drug therapy for acute myeloid leukemia

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias

Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy

Activating mutations in ALK provide a therapeutic target in neuroblastoma

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Suchergebnisse filtern